骨肿瘤的外科治疗及相关基础研究，大段骨缺损的创伤修复重建及相关基础研究（包括医工交叉、材料学）

Surgical treatment of bone tumors and related basic research, repair and reconstruction of large bone defects and related basic research (including medical worker intersection, material science)

1、同济大学附属第十人民医院骨科行政副主任、骨与软组织肿瘤科主任

Deputy Director of Department of Orthopaedics and Director of Department of Bone and Soft Tissue Tumors, Tenth People's Hospital, Tongji University

2、同济大学骨与软组织肿瘤诊疗中心主任

Director of the Center for Bone and Soft Tissue Tumor Diagnosis and Treatment at Tongji University

3、中华医学会骨科分会骨肿瘤学组委员

Member of the Bone Oncology Group of the Chinese Medical Association Orthopaedic Branch

4、中国医药教育协会肢体肿瘤分会副主任委员

Vice chairman of Limb tumor branch of Chinese Medical Education Association

5、上海市中西医结合学会骨伤科专委会创伤学组副组长

Deputy Head of Trauma Group, Shanghai Association of Integrated Traditional Chinese and Western Medicine

6、上海市优秀学术带头人

Shanghai Excellent Academic Leader

主持的主要科研项目(Leading major research projects)：

1、国家自然科学基金面上项目，82072963，Circ_0081001/DDX3X/KLF4分子轴促进骨肉瘤侵袭和转移的作用和机制研究，2021/1/1-2024/12/31，55万元，结题，主持，(National Natural Science Foundation, NSFC 82072963）

2、国家自然科学基金面上项目，81872174、LncRNA ODRUL/miR-6874-3p/IL-6通路促进骨肉瘤侵袭、转移的作用及机制研究、2019/1/1-2022/12/31，57万元、结题、主持(National Natural Science Foundation, NSFC 81872174 )。

3、国家自然科学基金面上项目，81572630、长链非编码RNA OMRUL调控ABCB1介导骨肉瘤多药耐药发生、发展的分子机制研究、2016/01-2019/12、60万元、结题、主持(National Natural Science Foundation, NSFC 81572630)。

4、国家自然基金青年项目，30700850、应用RNA 干扰技术双通道下调Bcl-2 和cyclinD1 基因增强耐药骨肉瘤化疗敏感性的研究、2008/01-2010/12、16万元、已结题、主持(National Natural Science Foundation, NSFC 30700850)。

5、上海市科委项目（优秀学术带头人项目），19XD1402900、骨肿瘤保肢及其功能重建关键技术创新与应用、2019/05-2022/04、40万元、在研、主持(Shanghai Excellent Academic Leadership Program, 19XD1402900)。

6、上海市科委项目（浦江人才计划），13PJD023、髓腔内壁形态改变后骨-骨水泥界面的仿真形态学、机械微力学及生物学作用机制的研究、2013/09-2015/08、20万元、已结题、主持(Shanghai Pu-Jiang Talent Program, 13PJD023)。

7、上海市自然科学基金面上项目，25ZR1401294、靶向激活HTR2B通过CXCL10-CXCR3/ITGAM途径增强骨肉瘤免疫 治疗效果的作用机制研究、2025/07-2028/06、20万元、在研、主持(Shanghai Natural Science Foundation, 25ZR1401294)。

近五年发表的代表性论著(Representatives published in the past five years)：

1、Huang Z, Zhu J, Hu J, Wang X, Ma X, Xu E, Zhu K, Zhang C*. Activation of HTR2B Suppresses Osteosarcoma Progression through the STAT1-NLRP3 Inflammasome Pathway and Promotes OASL1+ Macrophage Production to Enhance Antitumor Immunity. Adv Sci (Weinh). 2025 Aug;12(29):e15276.

2、Xu E, Huang Z, Zhu K, Hu J, Ma X, Wang Y, Zhu J, Zhang C*.Thrombospondin 1 Promotes Cytoskeleton Remodeling, Dedifferentiation, and Pulmonary Metastasis through ITGA1 and ITGA6 in Osteosarcoma. Int J Biol Sci. 2025 Feb 18;21(5):2083-2100.

3、Wang Y, Ma X, Xu E, Huang Z, Yang C, Zhu K, Dong Y, Zhang C*.Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index. Clin Transl Med. 2024 Feb;14(2):e1586..

4、Zhang CL*, Hu J, Jiang Y, Tan S, Zhu K, Xue C, Dai Y, Chen F. Biomineralization-inspired synthesis of amorphous manganese phosphates for GLUT5-targeted drug-free catalytic therapy of osteosarcoma. Nanoscale. 2022 Jan 20;14(3):898-909.

5、 Hu J, Jiang Y, Tan S, Zhu K, Cai T, Zhan T, He S, Chen F, Zhang C*.Selenium-doped calcium phosphate biomineral reverses multidrug resistance to enhance bone tumor chemotherapy. Nanomedicine. 2021 Feb;32:102322.